24.04.2015 - AstraZeneca has boosted its oncology portfolio by signing a US$1.275bn agreement with Innate Pharma. The companies plan to further the development of Innate’s tumour-targeting antibody.
Under the terms of the co-development and commercialisation agreement, the Marseille-based biotech will receive cash payments of up to US$1.275bn (€1.17bn) as well as double digit royalties on sales. AstraZeneca and its biologics R&D arm Medimmune gain exclusive global rights to co-develop and commercialise IPH2201 in combination with MEDI473, an anti-PD-L1 immune checkpoint inhibitor developed by MedImmune. The Swedish-British pharma giant also gains access to IPH2201 in monotherapy and other combinations in certain areas.
In addition to an initial payment of US$250m (€230m), AstraZeneca will grant further regulatory and sales-related milestones of up to US$925m (€851m). AstraZeneca will book all sales and will pay Innate double-digit royalties on net sales. Innate retains the right to co-promote in Europe with a 50% profit share in the territory.
Currently in Phase II development, IPH2201 is a potential first-in-class humanised anti-NKG2A antibody. The checkpoint receptor NKG2A inhibits the anti-cancer functions of Natural Killer (NK) and cytotoxic cells.
16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.
14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.